A strain of Bifidobacterium bifidum VB184 producing L-tryptophan and its application and culture device

By screening and preserving the VB184 strain of Bifidobacterium bifidobacterium, the problem of insufficient production stability and acid-tolerant pancreatic fluid in the prior art was solved, and efficient secretion of L-tryptophan and preparation for treatment were achieved. Fermentation broth and bacterial suspension have improved the ability to prevent and treat various diseases.

CN118562688BActive Publication Date: 2024-11-22HANGZHOU VICROBX BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411063126.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-22
Estimated Expiration
2044-08-05

AI Technical Summary

Technical Problem

In the prior art, there are fewer methods for producing L-tryptophan using recombinant microorganisms, and the stability and acid-tolerant pancreatic fluid in vivo are insufficient, making it difficult to effectively regulate L-tryptophan metabolism to prevent and treat related diseases.

Method used

A strain of Bifidobacterium bifidum VB184 was screened and preserved. This strain was able to efficiently secrete L-tryptophan and resist gastric acid, pancreatic juice and intestinal fluid. It was used to prepare fermentation broth and bacterial suspension for regulation. L-tryptophan metabolism prevents, alleviates and treats diseases caused by lack of L-tryptophan.

Benefits of technology

It has achieved efficient and stable secretion of L-tryptophan in the body, improved tolerance to gastric acid, pancreatic juice and intestinal fluid, provided effective drugs and production methods for the treatment of L-tryptophan deficiency-related diseases, and enhanced the dosage of ability to prevent and treat major diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118562688B_ABST
    Figure CN118562688B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of microorganisms. The present invention proposes a strain of Bifidobacterium bifidum VB184 producing L-tryptophan and its application and culture device. The Bifidobacterium bifidum VB184 was deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration on September 8, 2023, with a deposit number of CGMCC No. 28408. The Bifidobacterium bifidum VB184 of the present invention can produce a high amount of L-tryptophan, has a strong ability to resist gastric acid, pancreatic juice and intestinal juice, and still has a high stability in intestinal juice, and can be used to regulate L-tryptophan metabolism, prevent, alleviate and / or treat related diseases caused by lack of L-tryptophan.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of microorganisms, and in particular to a strain of Bifidobacterium bifidum VB184 producing L-tryptophan and an application and a culture device thereof. Background Art

[0002] Tryptophan is an essential amino acid in the human and animal bodies and is a necessary element for protein construction. However, due to the lack of endogenous synthesis capacity, external intake becomes necessary. As a precursor for the production of key bioactive substances such as 5-hydroxytryptamine, melatonin and kynurenine, it plays an irreplaceable role in the complex process of maintaining life. In the medical field, L-tryptophan occupies a core position in compound amino acid formulas and injections, aiming to assist patients with protein malnutrition and improve nutritional status during postoperative recovery. Recent studies have revealed that tryptophan and its metabolites play a key role in the prevention and treatment of a variety of major diseases, including cancer, inflammation, liver and kidney diseases, diabetes, immune disorders and neurodegenerative diseases, showing its new potential in medical research. In the body, L-tryptophan can produce 5-hydroxytryptamine, a precursor of neurohormones, with the participation of vitamin B6, thereby promoting sleep and mental stability. In the field of food and feed industry, the addition of L-tryptophan improves the integrity of nutrients and the efficient utilization of protein, reflecting its important value in enhancing the nutritional value of food and animal feed.

[0003] L-tryptophan can be produced by chemical synthesis, protein hydrolysis, enzymatic conversion, and direct fermentation. With the advancement of science, the method of producing tryptophan using recombinant microorganisms (such as Escherichia coli) has become practical and dominant, but the production of L-tryptophan using natural and safe microorganisms is still rare.

[0004] To this end, the present invention will screen functional probiotics with the ability to produce L-tryptophan from the human intestine, providing new ideas for the development of drugs with functions such as enhancing immunity, preventing and treating various major diseases, and regulating sleep. Summary of the invention

[0005] The present invention aims to solve at least one of the technical problems existing in the prior art to at least a certain extent.

[0006] To this end, in a first aspect of the present invention, the present invention provides a Bifidobacterium bifidum Bifidobacterium bifidum VB184. According to an embodiment of the present invention, the Bifidobacterium bifidum VB184 was deposited in the General Microbiological Center of China Microorganism Culture Collection Administration on September 8, 2023, with a deposit number of CGMCC No. 28408.

[0007] The Bifidobacterium bifidum VB184 screened by the present invention can secrete L-tryptophan, has strong resistance to gastric acid, pancreatic juice and intestinal juice, and still has high stability and L-tryptophan production ability in intestinal juice. The strain can be used to regulate L-tryptophan metabolism, prevent, alleviate and / or treat related diseases caused by L-tryptophan deficiency.

[0008] In a second aspect of the present invention, the present invention provides a fermentation broth. According to an embodiment of the present invention, the fermentation broth is fermented by the Bifidobacterium bifidum VB184 described in the first aspect. The fermentation broth of the present invention can be used to regulate L-tryptophan metabolism, prevent, alleviate and / or treat related diseases caused by L-tryptophan deficiency.

[0009] In the third aspect of the present invention, the present invention provides a bacterial suspension. According to an embodiment of the present invention, the bacterial suspension includes the Bifidobacterium bifidum VB184 described in the first aspect. The bacterial suspension of the present invention can be used to regulate L-tryptophan metabolism, prevent, alleviate and / or treat related diseases caused by L-tryptophan deficiency.

[0010] In the fifth aspect of the present invention, the present invention proposes the use of the Bifidobacterium bifidum VB184 described in the first aspect, the fermentation broth described in the second aspect, or the bacterial suspension described in the third aspect in the preparation of a medicament for treating diseases related to L-tryptophan deficiency. The medicament of the present invention can be used to regulate L-tryptophan metabolism, prevent, alleviate and / or treat related diseases caused by L-tryptophan deficiency.

[0011] In a sixth aspect of the present invention, the present invention provides a composition. According to an embodiment of the present invention, the composition comprises at least one of the Bifidobacterium bifidum VB184 described in the first aspect, the fermentation broth described in the second aspect, and the bacterial suspension described in the third aspect. The composition of the present invention can be used to regulate L-tryptophan metabolism, prevent, alleviate and / or treat related diseases caused by L-tryptophan deficiency.

[0012] In a seventh aspect, the present invention provides a method for producing L-tryptophan. According to an embodiment of the present invention, the method comprises: (1) culturing the Bifidobacterium bifidum VB184 inoculated in a culture medium according to the first aspect; (2) isolating L-tryptophan from the product of step (1). The Bifidobacterium bifidum VB184 according to an embodiment of the present invention can produce a high amount of L-tryptophan, and therefore, a large amount of L-tryptophan can be isolated from its culture.

[0013] In the eighth aspect of the present invention, the present invention provides a culture device or production device for the Bifidobacterium bifidum VB184 described in the first aspect, the fermentation broth described in the second aspect, the bacterial suspension described in the third aspect, or the composition described in the sixth aspect. The culture device or production device according to the embodiment of the present invention can mass-produce the Bifidobacterium bifidum VB184, fermentation broth, bacterial suspension, or composition described in the present invention.

[0014] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0016] Figure 1 This is a graph showing the survival rate test results of Bifidobacterium bifidum VB184 in artificial simulated gastric fluids at different pH values ​​according to an embodiment of the present invention;

[0017] Figure 2 This is a graph showing the survival rate test results of Bifidobacterium bifidum VB184 in simulated intestinal fluid according to an embodiment of the present invention;

[0018] Figure 3 Graph showing the detection result of the survival rate of Bifidobacterium bifidum VB184 in simulated pancreatic juice according to an embodiment of the present invention. DETAILED DESCRIPTION

[0019] Embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and intended to be used to explain the present invention, but should not be understood as limiting the present invention.

[0020] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include at least one of the features. In the description of the present invention, the meaning of "plurality" and "multiple" is at least two or two, such as two, two, three, three, etc., unless otherwise clearly and specifically defined.

[0021] In this document, the terms “include”, “have” or “comprises” are open expressions, that is, they include the contents specified in the present invention but do not exclude other contents.

[0022] As used herein, the term "optionally" generally means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0023] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0024] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.

[0025] As used herein, the terms "treatment" and "alleviation" both refer to the use of drugs to obtain the desired pharmacological and / or physiological effects. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, especially humans, and includes: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a strain, fermentation broth, bacterial suspension or composition to an individual to treat, cure, alleviate, improve, reduce or inhibit the individual's disease, including but not limited to administering a strain, fermentation broth, bacterial suspension or composition described herein to an individual in need.

[0026] As used herein, the term "carrier" includes any solvent, drug stabilizer, or combination thereof, which are known to those skilled in the art. Except where any conventional carrier is incompatible with the active ingredient, its use in treatment or pharmaceutical compositions is contemplated.

[0027] strain

[0028] In some embodiments, the present invention provides a Bifidobacterium bifidum VB184, which was deposited in the General Microbiological Center of China National Microbiological Culture Collection Administration on September 8, 2023, with a deposit number of CGMCC No. 28408.

[0029] According to some specific embodiments of the present invention, the above-mentioned Bifidobacterium bifidum VB184 may further include at least one of the following additional technical features:

[0030] According to some specific embodiments of the present invention, the Bifidobacterium bifidum VB184 has a 16S rRNA sequence as shown in SEQ ID NO:1.

[0031] The new strain of Bifidobacterium bifidum VB184 screened by the present invention can secrete L-tryptophan, has strong resistance to gastric acid, pancreatic juice and intestinal juice, and still has high stability in intestinal juice. It can be used to regulate L-tryptophan metabolism, prevent, alleviate and / or treat related diseases caused by L-tryptophan deficiency, and has high application value.

[0032] In this context, the term "Bifidobacterium bifidum" Bifidobacterium bifidum VB184", "Bifidobacterium bifidum VB184", "VB184 strain" and "VB184" are synonymous.

[0033] Fermentation Broth

[0034] In some embodiments, the present invention provides a fermentation broth, which is fermented by the aforementioned Bifidobacterium bifidum VB184. The fermentation broth of the present invention can be used to regulate L-tryptophan metabolism, prevent, alleviate and / or treat related diseases caused by L-tryptophan deficiency.

[0035] It should be noted that the "fermentation broth" of the present invention refers to the solution obtained after culturing Bifidobacterium bifidum VB184 for a period of time, which solution mainly contains Bifidobacterium bifidum VB184 and its metabolites; or the supernatant after further treatment by centrifugation, filtration, etc., which supernatant mainly contains the metabolites of Bifidobacterium bifidum VB184.

[0036] bacterial suspension

[0037] In some embodiments, the present invention provides a bacterial suspension, which includes the aforementioned Bifidobacterium bifidum VB184. The bacterial suspension of the present invention can be used to regulate L-tryptophan metabolism, prevent, alleviate and / or treat related diseases caused by L-tryptophan deficiency.

[0038] It should be noted that the bacterial suspension can be obtained by treating the above fermentation broth by means of centrifugation, resuspension, etc.

[0039] use

[0040] In some embodiments, the present invention provides the use of the aforementioned Bifidobacterium bifidum VB184, fermentation broth or bacterial suspension in the preparation of a drug for treating L-tryptophan deficiency-related diseases. The drug of the present invention can be used to prevent, alleviate and / or treat related diseases caused by L-tryptophan deficiency.

[0041] According to an embodiment of the present invention, the above-mentioned use may further include at least one of the following additional technical features:

[0042] According to an embodiment of the present invention, the L-tryptophan deficiency-related disease includes at least one of insomnia, anxiety, attention deficit hyperactivity disorder and migraine.

[0043] drug

[0044] The present invention provides a medicine, which comprises at least one of the above-mentioned Bifidobacterium bifidum VB184, fermentation broth or bacterial suspension.

[0045] According to an embodiment of the present invention, the above-mentioned medicine may further include at least one of the following additional technical features:

[0046] According to an embodiment of the present invention, it further comprises a pharmaceutically acceptable auxiliary material or carrier.

[0047] In this article, "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammals treated therewith. Preferably, "pharmaceutically acceptable" as described in the present invention refers to those approved by federal regulatory agencies or national governments or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopeias for use in animals, particularly humans.

[0048] As used herein, the term "pharmaceutically acceptable carrier" includes any solvent, drug stabilizer, or combination thereof, which are known to those skilled in the art. Except where any conventional carrier is incompatible with the active ingredient, its use in treatment or pharmaceutical compositions is covered.

[0049] In this article, the term "pharmaceutically acceptable excipient" may include any solvent suitable for a specific target dosage form. Except for any conventional excipients that are incompatible with the Bifidobacterium bifidum VB184 disclosed in the present invention, such as any adverse biological effects produced or interactions with any other components of the pharmaceutically acceptable composition in a harmful manner, their use is also within the scope of the present disclosure.

[0050] According to an embodiment of the present invention, at least one of the aforementioned Bifidobacterium bifidum VB184, fermentation broth and bacterial suspension is added or inoculated into the medicine, thereby further obtaining a medicine capable of preventing, alleviating and / or treating related diseases caused by lack of L-tryptophan.

[0051] For example, the aforementioned medicines include but are not limited to: medicines for human use and medicines for animals. The aforementioned medicines for animals may be for pets, livestock, or wild animals.

[0052] It should be noted that the characteristics and advantages described above for Bifidobacterium bifidum VB184 are also applicable to this drug and will not be repeated here.

[0053] Composition

[0054] In some embodiments, the present invention provides a composition comprising at least one of the above-mentioned Bifidobacterium bifidum VB184, fermentation broth and bacterial suspension. The composition of the present invention can be used to regulate L-tryptophan metabolism, prevent, alleviate and / or treat related diseases caused by L-tryptophan deficiency.

[0055] According to an embodiment of the present invention, the above composition may further include at least one of the following additional technical features:

[0056] According to an embodiment of the present invention, the composition further comprises an ingestible excipient and / or carrier.

[0057] According to an embodiment of the present invention, the excipient includes at least one selected from a binder, a disintegrant, a lubricant, a glidant, a stabilizer, a filler, a diluent and a sustained-release agent.

[0058] According to an embodiment of the present invention, the carrier includes at least one selected from sugars, cellulose and its derivatives, calcium phosphates, alkaline earth metal stearates, vegetable oils, nonionic surfactants, cationic surfactants, anionic surfactants, fatty alcohols and cereal hydrolyzed solids.

[0059] According to an embodiment of the present invention, the dosage form of the composition includes at least one selected from oral liquid, powder, granule, capsule, tablet, and pill.

[0060] method

[0061] In some embodiments, the present invention provides a method for producing L-tryptophan, comprising: (1) culturing the Bifidobacterium bifidum VB184 described in the first aspect inoculated in a culture medium; (2) isolating L-tryptophan from the product of step (1).

[0062] According to an embodiment of the present invention, the above method may further include at least one of the following additional technical features:

[0063] According to an embodiment of the present invention, the culture medium includes: 0.4%~0.5% peptone, 0.4%~0.5% beef extract, 0.5%~1% tryptone, 0.4%~0.5% yeast extract powder, 0.5%~1% glucose, 0.1%~0.2% Tween 80, 0.1%~0.2% dipotassium hydrogen phosphate, 0.5%~1% sodium acetate, 0.1%~0.2% triammonium citrate, 0.02%~0.03% zinc sulfate heptahydrate, and 0.01%~0.02% magnesium sulfate heptahydrate.

[0064] According to an embodiment of the present invention, the inoculation ratio of the Bifidobacterium bifidum VB184 in the culture medium is 0.05%-0.2%.

[0065] According to an embodiment of the present invention, the culturing is performed at 37° C. under static conditions.

[0066] According to an embodiment of the present invention, the culturing time is 12 to 20 hours.

[0067] Device

[0068] In some embodiments, the present invention provides a culture device or production device for the aforementioned Bifidobacterium bifidum VB184, fermentation broth, bacterial suspension or composition. The culture device or production device according to the embodiment of the present invention can realize mass production of the Bifidobacterium bifidum VB184, fermentation broth, bacterial suspension or composition described in the present invention.

[0069] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

Claims

1. A Bifidobacterium bifidum VB184, characterized in that The Bifidobacterium bifidum VB184 was deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration on September 8, 2023, with the deposit number CGMCC No. 28408.

2. A fermentation broth, characterized in that: The fermentation broth is obtained by fermenting the Bifidobacterium bifidum VB184 according to claim 1, and the fermentation broth contains the Bifidobacterium bifidum VB184 according to claim 1.

3. A bacterial suspension, characterized in that: The bacterial suspension comprises the Bifidobacterium bifidum VB184 according to claim 1.

4. A composition, characterized in that The composition comprises at least one of the Bifidobacterium bifidum VB184 according to claim 1, the fermentation broth according to claim 2, and the bacterial suspension according to claim 3.

5. The composition according to claim 4, characterized in that The dosage form of the composition includes at least one selected from oral liquid, powder, granule, capsule, tablet, and pill.

6. The composition according to claim 4, characterized in that The composition further comprises an excipient and / or a carrier.

7. The composition according to claim 6, characterized in that The excipients include at least one selected from a binder, a disintegrant, a lubricant, a glidant, a stabilizer, a filler, a diluent and a sustained-release agent.

8. The composition according to claim 6, characterized in that The carrier comprises at least one selected from sugars, calcium phosphates, stearic acid alkaline earth metal salts, vegetable oils, nonionic surfactants, cationic surfactants, anionic surfactants, fatty alcohols and cereal hydrolyzed solids.

9. The composition according to claim 8, characterized in that The sugars include cellulose.

10. A method for producing L-tryptophan, characterized in that: include: (1) Cultivating the Bifidobacterium bifidum VB184 described in claim 1 inoculated in a culture medium; (2) Separating L-tryptophan from the product of step (1).

11. The method according to claim 10, characterized in that The culture medium comprises: 0.4% to 0.5% peptone, 0.4% to 0.5% beef extract, 0.5% to 1% tryptone, 0.4% to 0.5% yeast extract powder, 0.5% to 1% glucose, 0.1% to 0.2% Tween 80, 0.1% to 0.2% dipotassium hydrogen phosphate, 0.5% to 1% sodium acetate, 0.1% to 0.2% triammonium citrate, 0.02% to 0.03% zinc sulfate heptahydrate, and 0.01% to 0.02% magnesium sulfate heptahydrate.

12. The method according to claim 10, characterized in that The inoculation ratio of the Bifidobacterium bifidum VB184 in the culture medium is 0.05%-0.2%.

13. The method according to claim 10, characterized in that The culture was carried out at 37°C under static conditions.

14. The method according to claim 10, characterized in that The culture time is 12 to 20 hours.